Inclisiran clinical trials
Also written KJX839, ALN-PCSSC and Leqvio.
How each study uses inclisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the inclisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Dec 2021 · LEQVIO · NDA 214012 (FDA, Drugs@FDA)
- European Union
- 9 Dec 2020 · Leqvio · EMEA/H/C/005333 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 9 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 11 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 37 · Other 14
Novartis Pharmaceuticals (30) · The Medicines Company (6) · Duke University (2) · University of Oxford (1) · University of Cambridge (1) · Alnylam Pharmaceuticals (1) · Seoul National University Bundang Hospital (1) · First Affiliated Hospital of Xinjiang Medical University (1)
Often tested with
Tested in the same studies.
Alirocumab (2) · Pelacarsen (1) · Statins (1) · Ezetimibe (1) · Bempedoic acid (1) · Evolocumab (1) · QCZ484 (1) · Bempedoic Acid/Ezetimibe (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10, 2 in phase 3
Studies that test inclisiran, phase 3 first.
- Feb 2027Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesPhase 3 · Novartis Pharmaceuticals
- May 2027Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseasePhase 3 · Novartis Pharmaceuticals
- Nov 2026LATAM LOWERS LDL-CPhase 4 · Novartis Pharmaceuticals
- Dec 2026Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationPhase 1 · Novartis Pharmaceuticals
- Dec 2026Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial InfarctionPhase 4 · Novartis Pharmaceuticals
- Dec 2026VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart DiseasePhase 4 · Duke University
- Apr 2027A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaPhase 2 · Novartis Pharmaceuticals
- Apr 2027Inclisiran Effectiveness in China: a Pragmatic Randomized TrialPhase 4 · Novartis Pharmaceuticals
- May 2027Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionPhase 4 · University Medical Centre Ljubljana
- Aug 2027Comparing Inclisiran Versus Statin for Primary AldosteronismNot applicable · Third Military Medical University
Studies
Open first, then newest update. How each study uses inclisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 51
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionRecruitingPhase 4Duke UniversityNCT06909565Written as Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Comparing Inclisiran Versus Statin for Primary AldosteronismRecruitingNot applicableThird Military Medical UniversityNCT07884955Written as inclisiran
- LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringRecruitingPhase 4University of California, San DiegoNCT06865885Written as Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi ArabiaNot yet recruitingPhase 4Novartis PharmaceuticalsNCT07684469Written as inclisiran
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationRecruitingPhase 1Novartis PharmaceuticalsNCT07626281Written as Inclisiran formulation containing PS80
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesRecruitingPhase 3Novartis PharmaceuticalsNCT05682378Written as Inclisiran
- Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesRecruitingPhase 3Novartis PharmaceuticalsNCT07102628Written as Inclisiran
- Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeNot yet recruitingPhase 4Seoul National University Bundang HospitalNCT07799779Written as Inclisiran
- A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaRecruitingPhase 2Novartis PharmaceuticalsNCT07610278Written as Inclisiran
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingPhase 3Novartis PharmaceuticalsNCT06597006Written as Inclisiran
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingPhase 4University Medical Centre LjubljanaNCT07581808Written as Inclisiran
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingPhase 3Novartis PharmaceuticalsNCT06597019Written as Inclisiran
- LATAM LOWERS LDL-CRecruitingPhase 4Novartis PharmaceuticalsNCT06501443Written as KJX839
- The Prevent Coronary Artery Disease TrialRecruitingPhase 3Icahn School of Medicine at Mount SinaiNCT06494501Written as Inclisiran
- Effects of Inclisiran Combined with Statins on the Morphology of Coronary Vulnerable PlaquesRecruitingPhase 4Nanjing First Hospital, Nanjing Medical UniversityNCT06338293Written as Inclisiran sodium
- Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid UltrasoundNot yet recruitingPhase 4First Affiliated Hospital of Xinjiang Medical UniversityNCT06586684Written as Inclisiran
- Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart DiseaseNot yet recruitingPhase 4Jose Seijas AmigoNCT06421363Written as Inclisiran
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05030428Written as Inclisiran sodium 300 mg
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05739383Written as Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
See all 51 studies that test inclisiran →
Given beside what is tested · 1 — inclisiran is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with inclisiran
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaCompletedPhase 2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07421232Written as Inclisiran (Leqvio®) 300mg
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT05004675Written as Inclisiran
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Comparing Inclisiran Versus Statin for Primary AldosteronismOct 21, 2026NCT07884955
Codes
What other systems call inclisiran · ClinicalTrials.gg INT006414
- MeSH (NLM) C585830ALN-PCSConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UOW2C71PG5INCLISIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2588243One source FDA
- Wikidata Q48969359inclisiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170062InclisiranOne source FDA
- DrugBank DB14901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585830 | ALN-PCS | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UOW2C71PG5 | INCLISIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2588243 | — | One source FDA |
| Wikidata | Q48969359 | inclisiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170062 | Inclisiran | One source FDA |
| DrugBank | DB14901 | — | One source Wikidata |
Also registered as inclisiran sodium (UNII UPC6BTX7PY · RxNorm 2588259).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.